You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,714,313


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,714,313
Title: Simple method for detecting inhibitors of retroviral replication
Abstract:The present invention relates, in general, to a DNA segment. In particular, the present invention relates to a DNA segment comprising a selectable marker gene, a DNA segment comprising a selectable marker gene inserted into a retrotransposon, cells containing these DNA segments, and methods of using these DNA segments and cells. The present invention further relates to a vector comprising a selectable marker gene inserted into a retrotransposon, wherein the retrotransposon comprises a retroviral reverse transcriptase/RNase H gene domain and wherein the selectable marker gene contains an intron inserted into a coding sequence of the marker gene and the intron is in antisense orientation relative to transcription of the marker gene and in sense orientation relative to transcription of the retrotransposon.
Inventor(s): Garfinkel; David J. (Frederick, MD), Nissley; Dwight V. (Frederick, MD), Curcio; Joan M. (Albany, NY), Strathern; Jeffrey N. (Frederick, MD)
Assignee: United States of America as represented by the Department of Health and (Washington, DC)
Application Number:08/449,207
Patent Claims:1. A vector comprising a selectable marker gene inserted into a retrotransposon, wherein the retrotransposon comprises a retroviral reverse transcriptase/RNase H gene domain and wherein the selectable marker gene contains an intron inserted into a coding sequence of the marker gene and the intron is in antisense orientation relative to transcription of the marker gene and in sense orientation relative to transcription of the retrotransposon.

2. The vector of claim 1, wherein the retrotransposon is a yeast Ty element.

3. The vector of claim 1, wherein the reverse transcriptase/RNase H gene domain is an HIV- 1 reverse transcriptase/RNAse H gene domain.

4. The vector of claim 1, wherein the reverse transcriptase/RNase H gene domain is an HIV-2 reverse transcriptase/RNAse H gene domain.

5. The vector of claim 1, wherein the reverse transcriptase/RNase H gene domain is a feline immunodeficiency virus reverse transcriptase/RNAse H gene domain.

6. The vector of claim 1, wherein the reverse transcriptase/RNAse H gene domain is an avian immunodeficiency virus reverse transcriptase/RNAse H gene domain.

7. The vector of claim 1, wherein the reverse transcriptase/RNase H gene domain is selected from the group consisting of a HIV-2, simian immunodeficiency virus, bovine immunodeficiency virus, and equine infectious anemia virus.

8. The vector of claim 1, wherein the retrotransposon is under transcriptional control of an inducible promoter.

9. The vector of claim 1, wherein the selectable marker gene is a yeast HIS3 gene.

10. The vector of claim 1, wherein the intron is a yeast artificial intron.

11. A cell transformed with the vector of claim 1.

12. The vector of claim 2, wherein the retrotransposon is Tyl.

13. A cell transformed with the vector of claim 3.

14. A cell transformed with the vector of claim 4.

15. The vector of claim 8, wherein the inducible promoter is GAL1 promoter.

16. A method of screening for a compound with the ability to inhibit retroviral replication comprising

(a) contacting the cell of claim 11 with the compound,

(b) culturing the cell in selective media and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits retroviral replication.

17. A method of screening for a compound with the ability to inhibit reverse transcriptase comprising

(a) contacting the cell of claim 11 with the compound,

(b) culturing the cell in selective media and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits reverse transcriptase.

18. A method of screening for a compound with the ability to inhibit HIV-1 replication comprising

(a) contacting the cell of claim 13 with the compound,

(b) culturing the cell in selective media and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits HIV-1 replication.

19. A method of screening for a compound with the ability to inhibit HIV-2 replication comprising

(a) contacting the cell of claim 14 with the compound,

(b) culturing the cell in selective media and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits HIV-2 replication.

20. A method of screening for a compound with ability to inhibit retroviral replication comprising

(a) culturing a cell that is transformed with a vector comprising a DNA segment comprising a selectable marker gene inserted into a retrotransposon wherein the selectable marker gene contains an intron inserted into a coding sequence of the gene and the intron is present in an antisense orientation relative to transcription of the marker gene and in a sense orientation relative to transcription of the retrotransposon, in selective media,

(b) contacting the cell with the compound, and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits retroviral replication.

21. A method of screening for a compound with ability to inhibit retrotransposition comprising

(a) culturing a cell that is transformed with a vector comprising a DNA segment comprising a selectable marker gene inserted into a retrotransposon wherein the selectable marker gene contains an intron inserted into a coding sequence of the gene and the intron is present in an antisense orientation relative to transcription of the marker gene and in a sense orientation relative to transcription of the retrotransposon, in selective media,

(b) contacting the cell with the compound, and

(c) detecting inhibition of growth of the cell, a compound that inhibits growth of the cell being a compound that inhibits retrotransposition.

Details for Patent 5,714,313

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2015-02-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2015-02-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2015-02-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.